• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    Immune Pharmaceuticals, Inc. (IMNP)

    0.40 Down 0.03(6.98%) 4:00PM EDT
    |After Hours : 0.41 Up 0.01 (2.50%) 4:00PM EDT - Nasdaq Real Time Price
    ProfileGet Profile for:
    Immune Pharmaceuticals, Inc.
    430 East 29th Street
    Suite 940
    New York, NY 10016
    United States - Map
    Phone: 646-440-9310
    Fax: 917-398-1915
    Website: http://www.immunepharmaceuticals.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Major
    Full Time Employees:9

    Business Summary 

    Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes targeted therapeutics for the treatment of inflammatory diseases and cancer. The company’s lead product candidate is Bertilimumab, a human monoclonal antibody, which is under Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn's disease. It is also developing AmiKet, a prescription topical analgesic cream, which is in Phase III clinical trial to treat peripheral neuropathies; NanomAbs technology platform, an antibody-drug conjugate platform for the treatment of cancer; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer, which is under Phase I/II clinical trials for the treatment of patients with solid tumors. The company has license, and other collaborative research and development arrangements with iCo Therapeutics Inc.; Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.; MabLife SAS; Lonza Sales AG; Dalhousie University; Shire Biochem, Inc.; and Endo Pharmaceuticals. The company was founded in 2010 and is headquartered in New York, New York.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Immune Pharmaceuticals, Inc.

    Key Executives 
    Dr. Daniel Gedeon Teper PharmD,MBA, 56
    Co-Founder, Chief Exec. Officer and Director
    Mr. John Militello , 42
    Principal Financial Officer, Chief Accounting Officer, VP of Fin. and Controller
    Mr. Christine J. Petraglia ,
    Director of Investor Relations
    Ms. Anna Baran J.D.,
    Director of Corp. Affairs
    Mr. G. John Mohr , 60
    Sr. VP of Bus. Devel.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders